Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
306.4 INR | +5.06% | +14.67% | +22.73% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.73% | 4.18B | |
-1.91% | 103B | |
+0.49% | 95.71B | |
+1.69% | 22.02B | |
-17.24% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.88% | 15.52B | |
+3.20% | 13.86B | |
+35.54% | 12.04B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Transcript : Biocon Limited, Q4 2022 Earnings Call, Apr 29, 2022